Industry news that matters to you.  Learn more

Archives for November 2011

Telatinib Effect on Biomarker is Associated With More Than Six Months Improvement in Progression-Free Survival for Stomach Cancer Patients

ACT Biotech, Inc., a clinical stage biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, announced that results from a Phase 2 gastric cancer trial of telatinib on biomarker response will be presented at the AACR-NCI-EORTC International Conference in San Francisco. The results demonstrate that patients who were treated with a combination regimen of telatinib, a potent and selective oral inhibitor of vascular endothelial growth factor receptor (VEGFR), capecitabine and cisplatin and who responded with a large decrease of a specific angiogenesis biomarker – the soluble form of VEGFR2 (sVEGFR2) – were found to have a lower risk of disease progression and death compared to patients with smaller decreases.

Independent Proficiency Panels Demonstrate Critical Value of Cross-Laboratory Assay Harmonization for Immune Biomarker Development

The Association for Cancer Immunotherapy (CIMT) Immunoguiding Program (CIP) and the Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute (CRI) today announced the publication of a joint paper discussing recent results of independent international, cross-laboratory immune assay harmonization studies. More than 120 academic, pharmaceutical, biotechnology, contract research, and government laboratories from the United States and Europe have participated in CIMT-CIP and CRI-CIC sponsored proficiency panels to test and compare immune response assays, including measurement variability and reproducibility. The collaboration between both organizations dedicated to cancer immunotherapy has enabled this successful program, which represents the largest in the field and delivers an important practical advance to the research community.

ICON PLC and Empire Genomics Partner for the Delivery of Personalised Medicine Services

ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, and Empire Genomics, a leading provider of genomic technologies that enable personalised medicine to be realised, today announced the formation of a strategic alliance.

GeneNews’ Sentinel Principle Used to Discover New Blood Based Biomarkers for Nasopharyngeal Carcinoma

GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, announced that a presentation entitled “Nasopharyngeal Carcinoma Biomarkers derived using Peripheral Blood Transcriptome” was given today at the 2011 Asia Pacific Cancer Conference, Kuala Lumpur, Malaysia.

Frost & Sullivan Lauds Advanced Cell Diagnostics for Its Highly Innovative In Situ Biomarker Detection Assay Kit

Based on its recent analysis of the in situ biomarker detection assay market, Frost & Sullivan recognizes Advanced Cell Diagnostics, Inc. with the 2011 North American Frost & Sullivan Technology Innovation Award for its RNAscope platform.